Cellectar Biosciences Stock Alpha and Beta Analysis
| CLRB Stock | USD 2.95 0.21 7.66% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Cellectar Biosciences. It also helps investors analyze the systematic and unsystematic risks associated with investing in Cellectar Biosciences over a specified time horizon. Remember, high Cellectar Biosciences' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Cellectar Biosciences' market risk premium analysis include:
Beta 1.94 | Alpha (1.02) | Risk 5.84 | Sharpe Ratio (0.15) | Expected Return (0.90) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Cellectar | Build AI portfolio with Cellectar Stock |
Cellectar Biosciences Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Cellectar Biosciences market risk premium is the additional return an investor will receive from holding Cellectar Biosciences long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Cellectar Biosciences. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Cellectar Biosciences' performance over market.| α | -1.02 | β | 1.94 |
Cellectar Biosciences expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Cellectar Biosciences' Buy-and-hold return. Our buy-and-hold chart shows how Cellectar Biosciences performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Cellectar Biosciences Market Price Analysis
Market price analysis indicators help investors to evaluate how Cellectar Biosciences stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Cellectar Biosciences shares will generate the highest return on investment. By understating and applying Cellectar Biosciences stock market price indicators, traders can identify Cellectar Biosciences position entry and exit signals to maximize returns.
Cellectar Biosciences Return and Market Media
The median price of Cellectar Biosciences for the period between Fri, Oct 3, 2025 and Thu, Jan 1, 2026 is 3.59 with a coefficient of variation of 24.87. The daily time series for the period is distributed with a sample standard deviation of 0.94, arithmetic mean of 3.79, and mean deviation of 0.75. The Stock received a lot of media exposure during the period. Price Growth (%) |
| Timeline |
1 | Will Cellectar Biosciences Inc. stock see insider buying - 2025 Macro Impact Weekly Chart Analysis and Trade Guides - nchmf.gov.vn | 10/17/2025 |
2 | Is Cellectar Biosciences Inc. stock a safe investment in uncertain markets - July 2025 Drop Watch Long-Term Safe Return Strategies - newser.com | 10/31/2025 |
3 | Can Cellectar Biosciences Inc. stock surprise with earnings upside - Analyst Downgrade Free High Return Stock Watch Alerts - newser.com | 11/03/2025 |
4 | Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Thursday, November 13, 2025 | 11/06/2025 |
5 | Cellectar Biosciences Expected to Announce Earnings on Thursday | 11/11/2025 |
6 | Cellectar Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update | 11/13/2025 |
7 | Roth Capital Has Strong Forecast for CLRB FY2025 Earnings | 11/18/2025 |
8 | Is Cellectar Biosciences Inc. stock supported by strong fundamentals - Price Action High Accuracy Trade Alerts - Newser | 12/04/2025 |
9 | Disposition of 198 shares by Neis John of Cellectar Biosciences at 3.6969 subject to Rule 16b-3 | 12/12/2025 |
10 | Cellectar Biosciences Announces Multi-Year Supply Agreement with Ionetix for Alpha-Emitting Radioisotopes - Quiver Quantitative | 12/16/2025 |
11 | Acquisition by Jarrod Longcor of 10000 shares of Cellectar Biosciences at 5.25 subject to Rule 16b-3 | 12/24/2025 |
12 | Cellectar Biosciences, Inc. Short Interest Down 31.1 percent in December | 12/29/2025 |
About Cellectar Biosciences Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Cellectar or other stocks. Alpha measures the amount that position in Cellectar Biosciences has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
Cellectar Biosciences Upcoming Company Events
As portrayed in its financial statements, the presentation of Cellectar Biosciences' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Cellectar Biosciences' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Cellectar Biosciences' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Cellectar Biosciences. Please utilize our Beneish M Score to check the likelihood of Cellectar Biosciences' management manipulating its earnings.
| 14th of March 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 14th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Cellectar Biosciences
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Cellectar Biosciences Backtesting, Cellectar Biosciences Valuation, Cellectar Biosciences Correlation, Cellectar Biosciences Hype Analysis, Cellectar Biosciences Volatility, Cellectar Biosciences History and analyze Cellectar Biosciences Performance. For information on how to trade Cellectar Stock refer to our How to Trade Cellectar Stock guide.You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Cellectar Biosciences technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.